Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lansoprazole sulfone is a small molecule and an oxidative metabolite of the proton pump inhibitor (PPI) lansoprazole. It is considered an experimental compound and is not approved for clinical use as a therapeutic agent. Lansoprazole sulfone has been identified as a human metabolite of lansoprazole and may be referred to in pharmaceutical research as an impurity or related substance during drug synthesis or metabolism studies. Its mechanism of action would be expected to mirror that of its parent compound by inhibiting the hydrogen/potassium-stimulated ATPase (proton pump) in gastric parietal cells; however, there are no established indications or clinical uses for this specific metabolite[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lansoprazole sulfone.